AI assistant
SCI Investor Presentation 2015
52383_rns_2015-03-17_bc5e3d5c-f37a-4943-a32c-9802544a6c65.pdf
Investor Presentation
Open in viewerOpens in your device viewer
SCI PHARMTECH, ING.
簡報
procedure Thainform Forwardterium Leola
All-HescoryList.Count > 0 these Forwardten inn, Enchind in Michon
Xol ardAckion, Enabled a False and r
CLOSE EXOTORIC + Teres, NYL !! Store population Prosentern Mobile which I is coast plasp: Dispatch, var MII Reading at OleVariable r-way
d destoryTodes + 01 MALDE HARGOLYLAST COMME . HAR I dioryLift Delate Office or 97 Highlip Ladas in Ristory List. Add
DES
RicertyTodes is Newtodes: ar brownsteads then hegin
Doctor Course I'm Falue.
Mel Andex ; a UEZ; Ituna, Index02
AE MANDICON - - 1 About
UP J. ftems, Promer (0, U914
員工數Employee:212 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣697佰萬元(NTD 697mn) 營業項目Business: 原料藥API(54.59%) 中間體Intermediate(39.62%) 特用化學品 Custom-made chemicals(5.79%)
公司概況 Outline
| Y2013 | Y2014 | |||
|---|---|---|---|---|
| 歐 洲Europe |
36.01% | 42.65% | ||
| 美 洲America |
22.80% | 21.70% | ||
| 亞 洲Asia |
24.00% | 18.18% | ||
| 國 內Taiwan |
17.19% | 16.63% | ||
| 澳 洲Australia |
0.00% | 0.84% | ||
| 計Total 合 |
100.00% | 100.00% |
Unit: K NTD
| 2014 | 2015 to date | |
|---|---|---|
| 營收Sales | 1,491,862 | 176,262 |
| 營業成本COGS | (1,012,509) | (112,193) |
| 毛利Gross Profit | 479,353 | 64,069 |
| 毛利率 GP Ratio | 32.1% | 36.3% |
| 營業費用Operating Expenses | (183,891) | (21,979) |
| 營業利益Operating Income | 295,462 | 42,090 |
| 營業外損益Non-Operating In/Ex | 39,671 | 64 |
| 稅前淨利 Net Profit before Tax | 335,133 | 42,154 |
| 所得稅Income Tax | ||
| 本期淨利Net Profit after Tax |
產品組合-Products
| Y2012 | % | Y2013 | % | Y2014 | % |
|---|---|---|---|---|---|
| V.A. | 18.66% | PGA | 18.31% | PGA | 17.49% |
| PGA | 16.61% | Di-VaNa | 16.92% | Di-VANa | 10.09% |
| Di-VaNa | 15.97% | S20/38 | 8.39% | LPF.Na | 8.74% |
| PPON | 7.88% | V.A. | 8.23% | S20/38 | 8.25% |
| Pent-2 | 4.78% | LPF.Na | 6.58% | V.A. | 8.15% |
| 5-HMT | 4.33% | PPON | 6.53% | DBS | 4.60% |
| M85 | 3.89% | 5-HMT | 4.51% | 5-HMT | 4.12% |
| DBS | 2.73% | PEB.Na | 3.98% | NaVA | 3.65% |
| M115 | 2.59% | NaVa | 3.34% | Pent-2 | 3.64% |
| M74 | 2.18% | DBS | 2.63% | T115 | 3.33% |
| Total | 79.62% | Total | 79.42% | Total | 72.06% |
| No. | Product | $\frac{0}{0}$ | 2015 Sales (NT\$) |
|---|---|---|---|
| 1 | HOCLQ Sulfate | 22.96% | 77,267,509 |
| $\overline{2}$ | PGA | 17.57% | 59, 123, 253 |
| $\overline{3}$ | Di-VANa | 9.28% | 31,236,894 |
| $\overline{\mathbf{4}}$ | V.A. | 8.08% | 27, 195, 862 |
| 5 | LPF.Na | 7.66% | 25,765,273 |
| 6 | DBS | 6.16% | 20,723,298 |
| $\overline{7}$ | 3-Azetidinol.Hcl | 3.83% | 12,899,411 |
| 8 | T115 | 3.17% | 10,682,000 |
| 9 | Pent-2 | 3.17% | 10,655,189 |
| 10 | NBE | 3.13% | 10,548,990 |
SCI
V DEDPM.
SCI PHARMTECH, INC.
$\rightarrow VA$
NaVa
Pyrogallolaldehyde ( PGA) - Benserazide
治療帕金森氏症之中間體 Intermediate for Parkinson's Disease
2015 sales: 59M
2個客戶 2 customers
產品介紹Product
Divalproex Sodium (Di-Va)
學名藥於2009推出 Generic came out in 2009 10個客戶 10 customers 2015 sales: 31M
Anti-inflammatory (Loxoprofen sodium)
日本市場200-300公噸 Japan market:200-300MT 2015 sales: 26M
S20/38
臨床藥物 Medication in clinical trial
Valproic Acid (VA)
20個客戶 20 customers 2015 sales: 27M
Sodium Valproate (NaVA)
24 客戶 24 customers 2015 sales: 9M
5-HMT – Ritonavir,Lopinavir
愛滋病藥物中間體 For AIDS treatment 2015 sales: 8M
產品介紹Product
Pentobarbital Sodium (鎮定安眠用, calmative)
Pent-2
Antidepressant (Duloxetine) 2013年底專利到期 Patent expired in the end of 2013 2014 sales: 12 M
Antidepressant (S-MMAA) Duloxetine之中間體 intermediate of Duloxetine 2014 sales: 27 M
- 5t: 15.3m sales
- Hydroxychloroquine sulfate: 18.6 m sales
- Propafenone: 16 m sales
- HDFN:19 m sales
GMP Status(GMP現況)
| API | CGMP certified |
CEP (EDQM) |
DMF (USA) |
MF (Japan) |
DMF (Canada) |
|---|---|---|---|---|---|
| (TFDA) | |||||
| Valproic Acid (*) |
2003 | 2004 | 2003 | 2008 | 2008 |
| Allopurinol | 2004 | 2003 | 2011 | ||
| Probucol | 2004 | 2004 | |||
| Sodium Valproate |
2004 | 2006 | |||
| Divalproex Sodium (**) |
2005 | 2005 | 2010 | ||
| Bisoprolol Fumarate |
2006 | ||||
| Pentobarbital Sodium |
2009 | 2 011 |
|||
| Propafenone Hydrochloride |
2010 | 2012 | 2010 | 2012 | 2012 |
| Methylphenidate HCl |
2 011 |
2014 | |||
| Duloxetine Hydrochloride |
2012 | 2014 | 2010/2011 | ||
| Thiopental acid |
2012 | ||||
| Loxoprofen Sodium Hydrate |
2012 | 2011 | |||
| Articaine Hydrochloride |
2013 | 2014 | |||
| Hydroxychloroquine Sulfate |
2014 | 2014 | |||
| Clindamycin Palmitate HCl |
2011 | ||||
| Cyclophosphamide | 2012 |
(*)(**) FDA inspection: Nov. 2005 / April 2012, (*) EDQM inspection: Nov. 2010
